Critical Election Day Victories for Psychedelics Continue the Industry’s Momentum
Key psychedelic drug ballot initiatives pass in Oregon and Washington, D.C. setting a bright future for mental health care in the U.S.
LAS VEGAS, NV, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) applauds the successful passage of two key psychedelic ballot initiatives in Oregon and the nation’s capital following the November 3rd election. These victories continues to highlight a critical and ongoing shift in support of medicinal psychedelics in the U.S.
Oregon’s Measure 109, a Psilocybin Therapy Initiative, will allow for the development of a state-regulated program for psilocybin-assisted therapy aimed at treating those suffering from debilitating mental health conditions such as depression, anxiety, PTSD, and addiction.
In a July 2020 interview with PSYC CEO David Flores, Sheri Eckert, one of the chief petitioners behind Measure 109, explained that “it’s important to create new options.” Eckert said psilocybin assisted therapy can help. “This approach will bring a new tool for mental health and wellness into the field of care, and we need this because our current treatment options are not working for enough people. For some, psilocybin therapy might even eliminate the need for daily dosing of psych meds, and that’s good news, because the goal is to heal, not to prescribe more pills.”
“Congratulations to Tom and Sheri Eckert for the tireless work they have put into Measure 109,” said Flores. “We are honored to have had the opportunity to share the important mission and message associated with Measure 109 through our Psychedelic Spotlight platform.”
Washington D.C.’s Initiative 81 decriminalizes several plant and fungi-based psychedelic substances. And with this passage, DC joins other cities including Denver, Oakland, and Santa Cruz, Calif., and Ann Arbor, Mich., which have already decriminalized plant and fungi-based psychedelics.
“We here at PSYC are quite encouraged with the passage of these ballot initiatives and how they further demonstrate the very viable path for the emergence of medicinal psychedelics as an industry,” Flores said. “We look forward to continuing to serve as a voice and resource for the advancement of medicinal psychedelics, helping to develop and shape what we believe is materializing into one of the most prominent and critical industries of our time.”
About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(702) 239-1919
psyc@globaltracsolutions.com
OTCPINK: PSYC
Key psychedelic drug ballot initiatives pass in Oregon and Washington, D.C. setting a bright future for mental health care in the U.S.
LAS VEGAS, NV, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) applauds the successful passage of two key psychedelic ballot initiatives in Oregon and the nation’s capital following the November 3rd election. These victories continues to highlight a critical and ongoing shift in support of medicinal psychedelics in the U.S.
Oregon’s Measure 109, a Psilocybin Therapy Initiative, will allow for the development of a state-regulated program for psilocybin-assisted therapy aimed at treating those suffering from debilitating mental health conditions such as depression, anxiety, PTSD, and addiction.
In a July 2020 interview with PSYC CEO David Flores, Sheri Eckert, one of the chief petitioners behind Measure 109, explained that “it’s important to create new options.” Eckert said psilocybin assisted therapy can help. “This approach will bring a new tool for mental health and wellness into the field of care, and we need this because our current treatment options are not working for enough people. For some, psilocybin therapy might even eliminate the need for daily dosing of psych meds, and that’s good news, because the goal is to heal, not to prescribe more pills.”
“Congratulations to Tom and Sheri Eckert for the tireless work they have put into Measure 109,” said Flores. “We are honored to have had the opportunity to share the important mission and message associated with Measure 109 through our Psychedelic Spotlight platform.”
Washington D.C.’s Initiative 81 decriminalizes several plant and fungi-based psychedelic substances. And with this passage, DC joins other cities including Denver, Oakland, and Santa Cruz, Calif., and Ann Arbor, Mich., which have already decriminalized plant and fungi-based psychedelics.
“We here at PSYC are quite encouraged with the passage of these ballot initiatives and how they further demonstrate the very viable path for the emergence of medicinal psychedelics as an industry,” Flores said. “We look forward to continuing to serve as a voice and resource for the advancement of medicinal psychedelics, helping to develop and shape what we believe is materializing into one of the most prominent and critical industries of our time.”
About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.
We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.
Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.
Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(702) 239-1919
psyc@globaltracsolutions.com
OTCPINK: PSYC
